Denali and Royalty Pharma Strike $275M Deal for Hunter Syndrome Treatment
Denali Therapeutics secures $275 million from Royalty Pharma for tividenofusp alfa, a promising therapy for Hunter syndrome awaiting FDA approval in April 2026.
/ 1 item
#DNLI↓